Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.
Ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyldopamine, was investigated at doses ranging from 1.09 to 2.34 mg/kg in 12 patients suffering from refractory congestive heart failure. In 7 patients ibopamine produced favorable effects, increasing cardiac index (+35%), stroke volume index (+27%), stroke work index (+30%) and decreasing systemic vascular resistances (-15%), total pulmonary resistances (-20%), pulmonary arteriolar resistances (-28%), whereas in 5 patients it was ineffective. Transient adverse reactions occurred in 3 patients.
Humar
F
F
Morgera
T
T
Maras
P
P
Camerini
F
F
D000328:Adult; D000368:Aged; D006328:Cardiac Catheterization; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives*; D004351:Drug Resistance; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D002316:Cardiotonic Agents; C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine